Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | APP | P05067 | 4/20 | 0.46 |
| ▸ | CTSS | P25774 | 6/20 | 0.45 |
| ▸ | CTSK | P43235 | 5/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | PTPRB | P23467 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21676555 | 1.00 | ATM (0.55) | ATMPPARGPPARAAPPCTSS | |
| SCHEMBL6479279 | 0.89 | CTSS (0.57) | ATMPPARAAPPCTSSCTSK | |
| SCHEMBL6479222 | 0.89 | CTSS (0.57) | ATMPPARAAPPCTSSCTSK | |
| SCHEMBL6479218 | 0.89 | CTSS (0.57) | ATMPPARAAPPCTSSCTSK | |
| SCHEMBL20577875 | 0.87 | ATM (0.54) | ATMPPARGPPARAAPPCTSS | |
| SCHEMBL20661659 | 0.87 | ATM (0.54) | ATMPPARGPPARAAPPCTSS | |
| SCHEMBL2617332 | 0.87 | CTSS (0.58) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL20577877 | 0.87 | ATM (0.54) | ATMPPARGPPARAAPPCTSS | |
| SCHEMBL14975258 | 0.87 | ATM (0.54) | ATMPPARGPPARAAPPCTSS | |
| SCHEMBL7019352 | 0.87 | ATM (0.54) | ATMPPARGPPARAAPPCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155355-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20120015909-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015909-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | ATM 2278/4885PPARG 807/4885PPARA 1797/4885 |
| US-20140155355-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | ATM 2278/4885PPARG 807/4885PPARA 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.